Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One cyclist's artery mystery could change how we spot hidden performance killers

NCT ID NCT07194330

Knowledge-focused Sponsor: Jesus Torres Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows one cyclist with a rare leg artery condition that limits blood flow during intense exercise. Researchers will review the cyclist's training power data and medical scans to better understand how the disease affects performance and how to diagnose it. The goal is to improve detection and treatment for athletes with similar issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1 person

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with the presence of external iliac artery endofibrosis pathophysiology, detected through performance-related suspicion, diagnosed, undergoing treatment, and in recovery

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Clinical diagnosis of external iliac artery endofibrosis confirmed by medical imaging (e.g., Doppler ultrasound, CT scan, or IVUS). Age between 18 and 65 years. Must be a regular cyclist (at least 500 training sessions per year for the past 5 years). Ability to complete physical performance tests (e.g., cycling power output measurements, Lactate Threshold test). No prior surgical intervention for external iliac artery endofibrosis or other lower extremity diseases Willingness to provide informed consent and participate in the study. Exclusion Criteria: History of major cardiovascular disease (e.g., heart attack, stroke). Pregnancy or breastfeeding. Use of medications that significantly affect vascular health (e.g., anticoagulants, steroids). Uncontrolled diabetes or other chronic metabolic disorders. Recent lower extremity surgery (within the last 6 months). Any condition that could interfere with the performance tests (e.g., neurological disorders, severe joint pain). Diagnosis of other vascular diseases (e.g., deep vein thrombosis, atherosclerosis) that could affect arterial function. History of systemic or local infections that may impact the vascular system. History of significant trauma or injury to the lower extremities (e.g., fractures, ligament tears). Any condition preventing safe participation in physical tests, including severe cardiovascular or musculoskeletal limitations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood flow velocity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood flow velocity Cycling Iliac artery occlusive disease Performance

Contacts and locations

Locations

  • C San Bartolome 4

    Estella-Lizarra, Navarre, 31292, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.